Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis

Anti-Bacterial Agents / administration & dosage Ceftriaxone / administration & dosage Daptomycin / administration & dosage Drug Resistance, Bacterial / drug effects Drug Therapy, Combination / methods Endocarditis / drug therapy Endocarditis, Bacterial / drug therapy Humans Microbial Sensitivity Tests / methods Streptococcus mitis / drug effects Streptococcus oralis / drug effects Vancomycin / administration & dosage beta-Lactams / metabolism
SEVs ceftriaxone daptomycin

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
06 2019
Historique:
received: 22 02 2019
accepted: 04 04 2019
pubmed: 10 4 2019
medline: 14 4 2020
entrez: 10 4 2019
Statut: epublish

Résumé

The viridans group streptococci (VGS) are a heterogeneous group of organisms which are important components of the normal human oral flora. Among the VGS, the

Identifiants

DOI: 10.1128/AAC.00386-19 PMID: 30962347 PMC: PMC6535512
pubmed: 30962347
pii: AAC.00386-19
doi: 10.1128/AAC.00386-19
pmc: PMC6535512
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
beta-Lactams 0
Vancomycin 6Q205EH1VU
Ceftriaxone 75J73V1629
Daptomycin NWQ5N31VKK

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R21 AI143229
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI134637
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI121400
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI130056
Pays : United States
Organisme : NIAID NIH HHS
ID : K08 AI113317
Pays : United States

Informations de copyright

Copyright © 2019 American Society for Microbiology.

Références

Antimicrob Agents Chemother. 2015;59(6):3529-40
pubmed: 25845880
Clin Infect Dis. 2011 Feb 1;52(3):285-92
pubmed: 21217178
Antimicrob Agents Chemother. 2000 Jul;44(7):1921-4
pubmed: 10858355
Infect Dis Ther. 2014 Jun;3(1):35-43
pubmed: 25134810
PLoS One. 2013 Aug 19;8(8):e71151
pubmed: 23990934
Diagn Microbiol Infect Dis. 2003 Nov;47(3):539-46
pubmed: 14596973
BMC Microbiol. 2011 Jan 18;11:13
pubmed: 21241511
Antimicrob Agents Chemother. 2009 Jun;53(6):2312-8
pubmed: 19332678
J Microbiol Methods. 2001 Jan;43(3):153-64
pubmed: 11118650
Antimicrob Agents Chemother. 2018 Jul 27;62(8):
pubmed: 29760141
Antimicrob Agents Chemother. 2013 Feb;57(2):1082-5
pubmed: 23254419
Antimicrob Agents Chemother. 2004 Dec;48(12):4665-72
pubmed: 15561842
Antimicrob Agents Chemother. 2015 May;59(5):2842-8
pubmed: 25753639
PLoS One. 2012;7(8):e43958
pubmed: 22952824
Cold Spring Harb Perspect Med. 2016 Nov 1;6(11):
pubmed: 27580748
Nat Microbiol. 2016 Oct 24;2:16194
pubmed: 27775684
Antimicrob Agents Chemother. 2012 Jun;56(6):3174-80
pubmed: 22470111
Microbiology. 2017 Oct;163(10):1502-1508
pubmed: 28942757
J Med Microbiol. 2017 Sep;66(9):1316-1323
pubmed: 28874232
Antimicrob Agents Chemother. 2011 Sep;55(9):4012-8
pubmed: 21709105
Antimicrob Agents Chemother. 2015 Apr;59(4):2102-12
pubmed: 25624330
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28264848
PLoS One. 2014 Sep 16;9(9):e107426
pubmed: 25226591
Infect Immun. 2008 May;76(5):1889-96
pubmed: 18316382
J Antimicrob Chemother. 2014 Aug;69(8):2148-54
pubmed: 24777900
J Infect Chemother. 2003 Dec;9(4):321-7
pubmed: 14691653
J Antimicrob Chemother. 2001 Jan;47(1):87-91
pubmed: 11152436
Ther Drug Monit. 2010 Apr;32(2):200-5
pubmed: 20216115
J Clin Microbiol. 2010 Nov;48(11):3829-35
pubmed: 20810781
J Antimicrob Chemother. 2017 Aug 1;72(8):2290-2296
pubmed: 28475731
Antimicrob Agents Chemother. 2013 Dec;57(12):6378-80
pubmed: 24080651
J Antimicrob Chemother. 2015;70(6):1738-43
pubmed: 25645208
Antimicrob Agents Chemother. 2010 Dec;54(12):5187-92
pubmed: 20921318
Curr Microbiol. 2018 Aug;75(8):1062-1067
pubmed: 29651552
Infect Immun. 2001 Mar;69(3):1373-80
pubmed: 11179301
Antimicrob Agents Chemother. 2019 Jan 29;63(2):
pubmed: 30509945
Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28115347
Antimicrob Agents Chemother. 2013 Jan;57(1):289-96
pubmed: 23114777
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28223392
Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E7077-E7086
pubmed: 27791134
J Biol Chem. 2014 Apr 25;289(17):11584-91
pubmed: 24616102
Antimicrob Agents Chemother. 2013 May;57(5):2319-25
pubmed: 23478959

Auteurs

Razieh Kebriaei (R)

Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan, USA.

Seth A Rice (SA)

Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan, USA.

Kyle C Stamper (KC)

Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan, USA.

Ravin Seepersaud (R)

University of California, San Francisco, San Francisco, California, USA.
San Francisco VA Medical Center, San Francisco, California, USA.

Cristina Garcia-de-la-Maria (C)

Infectious Diseases Service, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

Nagendra N Mishra (NN)

LA Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, USA.
The Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Jose M Miro (JM)

Infectious Diseases Service, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

Cesar A Arias (CA)

Center for Antimicrobial Resistance and Microbial Genomic, Division of Infectious Diseases, UTHealth McGovern Medical School, Houston, Texas, USA.
Center for Infectious Diseases, UTHealth School of Public Health, Houston, Texas, USA.
Molecular Genetics and Antimicrobial Resistance Unit, International Center for Microbial Genomics, Universidad El Bosque, Bogota, Colombia.

Truc T Tran (TT)

Center for Antimicrobial Resistance and Microbial Genomic, Division of Infectious Diseases, UTHealth McGovern Medical School, Houston, Texas, USA.

Paul M Sullam (PM)

University of California, San Francisco, San Francisco, California, USA.
San Francisco VA Medical Center, San Francisco, California, USA.

Arnold S Bayer (AS)

LA Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, USA.
The Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Michael J Rybak (MJ)

Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan, USA m.rybak@wayne.edu.
School of Medicine, Wayne State University, Detroit, Michigan, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Daptomycin Dose-Ranging Evaluation with...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Céphalosporines › Céfacétrile › Céfotaxime › Ceftriaxone › Daptomycin Dose-Ranging Evaluation with...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Peptides cycliques › Daptomycine › Daptomycin Dose-Ranging Evaluation with...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance microbienne aux médicaments › Résistance bactérienne aux médicaments › Daptomycin Dose-Ranging Evaluation with...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Daptomycin Dose-Ranging Evaluation with...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Endocardite › Daptomycin Dose-Ranging Evaluation with...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Endocardite › Endocardite bactérienne › Daptomycin Dose-Ranging Evaluation with...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Daptomycin Dose-Ranging Evaluation with...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Daptomycin Dose-Ranging Evaluation with...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Lactobacillales › Streptococcaceae › Streptococcus › Streptocoques viridans › Streptococcus mitis › Daptomycin Dose-Ranging Evaluation with...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Lactobacillales › Streptococcaceae › Streptococcus › Streptocoques viridans › Streptococcus oralis › Daptomycin Dose-Ranging Evaluation with...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Glycopeptides › Vancomycine › Daptomycin Dose-Ranging Evaluation with...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Daptomycin Dose-Ranging Evaluation with...